INDOMETHACIN (indomethacin) by Molecular Devices is cyclooxygenase inhibitors [moa]. First approved in 1984.
Drug data last refreshed 16h ago · AI intelligence enriched 2d ago
Indomethacin is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase enzymes to reduce inflammation, pain, and fever. It is an oral capsule indicated for various inflammatory and pain conditions. The drug has been a long-standing therapeutic option since its approval in 1984.
With LOE approaching and moderate competitive pressure (30/100), brand teams are likely focused on retention and cost management rather than growth expansion.
Cyclooxygenase Inhibitors
Nonsteroidal Anti-inflammatory Drug
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Rectal Indomethacin as Early Treatment for Acute Pancreatitis (INDOMAP Trial)
Study to Investigate the Potential Drug-Drug Interaction Between Elafibranor and Indomethacin
Comparative Effectiveness Between Indomethacin and Pancreatic Stenting in the Prevention of Post ERCP Pancreatitis
A Study to Compare 3 Doses of a Hormonal Intra-uterine Device Containing Levonorgestrel and Indomethacin With a Hormonal Intra-uterine Device Containing Only Levonorgestrel to Assess the Effect and Safety of the Combined Components
A Phase II Neoadjuvant Study of Apalutamide, Abiraterone Acetate, Prednisone, Degarelix and Indomethacin in Men With Localized Prostate Cancer Pre-prostatectomy
Worked on INDOMETHACIN at Molecular Devices? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Working on indomethacin offers experience in mature product management, competitive differentiation in crowded markets, and lifecycle optimization strategies. Career growth opportunities are limited by the LOE status, making this role best suited for professionals seeking stability or preparing for transition to newer pipeline assets.